vs

Side-by-side financial comparison of Marygold Companies, Inc. (MGLD) and Vivos Therapeutics, Inc. (VVOS). Click either name above to swap in a different company.

Marygold Companies, Inc. is the larger business by last-quarter revenue ($7.6M vs $3.8M, roughly 2.0× Vivos Therapeutics, Inc.). Marygold Companies, Inc. runs the higher net margin — -7.5% vs -180.3%, a 172.7% gap on every dollar of revenue. On growth, Vivos Therapeutics, Inc. posted the faster year-over-year revenue change (3.4% vs -4.5%). Over the past eight quarters, Vivos Therapeutics, Inc.'s revenue compounded faster (5.8% CAGR vs -1.5%).

Marygold Companies, Inc. is a U.S.-headquartered diversified holding company that operates across three core segments: financial services, specialty manufacturing, and consumer goods. It primarily caters to North American markets, driving long-term value growth via strategic investment in, and operational optimization of, its portfolio of subsidiary entities.

Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.

MGLD vs VVOS — Head-to-Head

Bigger by revenue
MGLD
MGLD
2.0× larger
MGLD
$7.6M
$3.8M
VVOS
Growing faster (revenue YoY)
VVOS
VVOS
+7.9% gap
VVOS
3.4%
-4.5%
MGLD
Higher net margin
MGLD
MGLD
172.7% more per $
MGLD
-7.5%
-180.3%
VVOS
Faster 2-yr revenue CAGR
VVOS
VVOS
Annualised
VVOS
5.8%
-1.5%
MGLD

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
MGLD
MGLD
VVOS
VVOS
Revenue
$7.6M
$3.8M
Net Profit
$-576.0K
$-6.9M
Gross Margin
74.0%
78.1%
Operating Margin
-8.3%
-166.8%
Net Margin
-7.5%
-180.3%
Revenue YoY
-4.5%
3.4%
Net Profit YoY
67.0%
-143.8%
EPS (diluted)
$-0.01
$-0.58

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MGLD
MGLD
VVOS
VVOS
Q4 25
$7.6M
$3.8M
Q3 25
$7.0M
$6.8M
Q2 25
$7.2M
$3.8M
Q1 25
$7.0M
$3.0M
Q4 24
$8.0M
$3.7M
Q3 24
$7.9M
$3.9M
Q2 24
$8.3M
$4.1M
Q1 24
$7.9M
$3.4M
Net Profit
MGLD
MGLD
VVOS
VVOS
Q4 25
$-576.0K
$-6.9M
Q3 25
$-356.0K
$-5.4M
Q2 25
$-1.5M
$-5.0M
Q1 25
$-1.0M
$-3.9M
Q4 24
$-1.7M
$-2.8M
Q3 24
$-1.6M
$-2.6M
Q2 24
$-1.9M
$-1.9M
Q1 24
$-529.0K
$-3.8M
Gross Margin
MGLD
MGLD
VVOS
VVOS
Q4 25
74.0%
78.1%
Q3 25
77.0%
58.0%
Q2 25
67.8%
55.2%
Q1 25
75.0%
50.0%
Q4 24
74.1%
56.7%
Q3 24
73.1%
60.5%
Q2 24
72.5%
65.4%
Q1 24
70.5%
56.7%
Operating Margin
MGLD
MGLD
VVOS
VVOS
Q4 25
-8.3%
-166.8%
Q3 25
-18.2%
-69.8%
Q2 25
-16.5%
-127.4%
Q1 25
-21.4%
-129.9%
Q4 24
-22.8%
-75.9%
Q3 24
-27.4%
-68.5%
Q2 24
-33.3%
-47.8%
Q1 24
-18.7%
-110.7%
Net Margin
MGLD
MGLD
VVOS
VVOS
Q4 25
-7.5%
-180.3%
Q3 25
-5.1%
-79.6%
Q2 25
-20.4%
-131.2%
Q1 25
-14.4%
-128.1%
Q4 24
-21.8%
-76.4%
Q3 24
-20.1%
-67.8%
Q2 24
-22.5%
-47.6%
Q1 24
-6.7%
-110.1%
EPS (diluted)
MGLD
MGLD
VVOS
VVOS
Q4 25
$-0.01
$-0.58
Q3 25
$-0.01
$-0.49
Q2 25
$-0.04
$-0.55
Q1 25
$-0.02
$-0.45
Q4 24
$-0.04
$0.41
Q3 24
$-0.04
$-0.40
Q2 24
$-0.05
$-0.60
Q1 24
$-0.01
$-1.63

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MGLD
MGLD
VVOS
VVOS
Cash + ST InvestmentsLiquidity on hand
$11.6M
$2.0M
Total DebtLower is stronger
$2.9M
Stockholders' EquityBook value
$22.7M
$-1.5M
Total Assets
$27.8M
$25.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MGLD
MGLD
VVOS
VVOS
Q4 25
$11.6M
$2.0M
Q3 25
$12.5M
$3.1M
Q2 25
$12.8M
$4.4M
Q1 25
$15.6M
$2.3M
Q4 24
$14.9M
$6.3M
Q3 24
$17.5M
$6.3M
Q2 24
$15.0M
$6.9M
Q1 24
$16.1M
$2.6M
Total Debt
MGLD
MGLD
VVOS
VVOS
Q4 25
$2.9M
Q3 25
Q2 25
Q1 25
Q4 24
$1.2M
Q3 24
$1.2M
Q2 24
$1.2M
Q1 24
Stockholders' Equity
MGLD
MGLD
VVOS
VVOS
Q4 25
$22.7M
$-1.5M
Q3 25
$22.9M
$2.5M
Q2 25
$23.0M
$4.6M
Q1 25
$24.3M
$4.4M
Q4 24
$23.4M
$8.0M
Q3 24
$25.5M
$7.7M
Q2 24
$26.6M
$6.3M
Q1 24
$28.4M
$582.0K
Total Assets
MGLD
MGLD
VVOS
VVOS
Q4 25
$27.8M
$25.2M
Q3 25
$28.4M
$25.6M
Q2 25
$30.4M
$26.0M
Q1 25
$33.5M
$11.3M
Q4 24
$33.0M
$15.3M
Q3 24
$35.9M
$15.3M
Q2 24
$32.9M
$15.8M
Q1 24
$33.7M
$11.8M
Debt / Equity
MGLD
MGLD
VVOS
VVOS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.15×
Q3 24
0.16×
Q2 24
0.19×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MGLD
MGLD
VVOS
VVOS
Operating Cash FlowLast quarter
$-908.0K
$-3.8M
Free Cash FlowOCF − Capex
$-5.3M
FCF MarginFCF / Revenue
-139.7%
Capex IntensityCapex / Revenue
0.0%
40.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-17.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MGLD
MGLD
VVOS
VVOS
Q4 25
$-908.0K
$-3.8M
Q3 25
$-533.0K
$-4.2M
Q2 25
$-3.3M
$-3.5M
Q1 25
$-1.2M
$-3.8M
Q4 24
$-770.0K
$-2.9M
Q3 24
$-893.0K
$-4.2M
Q2 24
$-1.9M
$-3.0M
Q1 24
$-658.0K
$-2.5M
Free Cash Flow
MGLD
MGLD
VVOS
VVOS
Q4 25
$-5.3M
Q3 25
$-562.0K
$-4.2M
Q2 25
$-3.4M
$-4.3M
Q1 25
$-3.9M
Q4 24
$-776.0K
$-3.1M
Q3 24
$-940.0K
$-4.4M
Q2 24
$-2.0M
$-3.1M
Q1 24
$-2.7M
FCF Margin
MGLD
MGLD
VVOS
VVOS
Q4 25
-139.7%
Q3 25
-8.1%
-62.6%
Q2 25
-46.8%
-111.6%
Q1 25
-129.9%
Q4 24
-9.7%
-84.0%
Q3 24
-11.9%
-113.4%
Q2 24
-23.8%
-76.7%
Q1 24
-78.0%
Capex Intensity
MGLD
MGLD
VVOS
VVOS
Q4 25
0.0%
40.0%
Q3 25
0.4%
1.2%
Q2 25
0.7%
20.2%
Q1 25
0.0%
4.0%
Q4 24
0.1%
4.5%
Q3 24
0.6%
5.0%
Q2 24
0.7%
1.5%
Q1 24
0.0%
4.4%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MGLD
MGLD

Fund Management Related Party$4.6M60%
Food Products$1.7M22%
Beauty Products$1.2M15%
Other$268.0K4%

VVOS
VVOS

Services$3.2M84%
Products$594.0K16%

Related Comparisons